ATS 2019 Virtual Final Program

219 Disease Severity of Patients with High Blood Eosinophil Counts Treated for COPD Exacerbation with or Without Oral Corticosteroids/ M. Kerkhof, I. Chaudhry, J. Kocks, I. Pavord, D. Halpin, O. Usmani, T. Morris, M. Alacqua, D. Price, Singapore, Singapore, p.A5958 220 Omega-3 Fatty Acid Intake and Respiratory Symptoms Among US Adults with COPD/ C.M. Lemoine Soto, E. Brigham, J.L. Woo, C. Hanson, M.C. McCormack, A.L. Koch, N. Putcha, N.N. Hansel, Baltimore, MD, p.A5959 221 Change in Daily Inhaler Use, Lung Function, and Oxygen Saturation in Association with Respiratory Symptoms in a Prospective Study of COPD Patients/ W.Y. Sun, C. Zhang, A.J. Synn, B.A. Coull, M.A. Mittleman, M.B. Rice, Boston, MA, p.A5960 222 Characterization of Chronic Obstructive Pulmonary Disease-Pulmonary Hypertension/ A. Balasubramanian, T.M. Kolb, R.L. Damico, P.M. Hassoun, M.C. McCormack, S.C. Mathai, Baltimore, MD, p.A5961 223 Clinical Features Predict New Strain Bacterial Exacerbation of COPD/ C. Pu, A. Mohan, S. Sethi, Buffalo, NY, p.A5962 CLINICAL POSTER DISCUSSION SESSION D24 AUTOIMMUNE DISEASE, DRUG-INDUCED, AND TRANSPLANT 9:15 a.m. - 11:15 a.m. KBHCCD Room C140/C142 (Level 1) Poster Viewing 9:15-10:00 Discussion 10:00-11:15 Chairing: A.L. Gray, MD, Durham, NC A.L. Olson, MD, Denver, CO 101 Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): The SENSCIS Trial/ O. Distler, K.B. Highland, M. Gahlemann, A. Azuma, A. Fischer, M. Mayes, G. Raghu, W. Sauter, M. Girard, M. Alves, E. Clerisme-Beaty, M. Kuwana, T.M. Maher, Zurich, Switzerland, p.A5963 102 Scleroderma-Related Mortality in the United States from 2003 to 2016/ P. Ratanawatkul, E.R. Fernandez Perez, Khon Kaen, Thailand, p.A5964 103 Comparative Evaluation of Radiographic and Autoimmune Serologic Features Between ANCA-Associated ILD and IPAF/ I. Bauer Ventura, M.E. Strek, A. Dua, R. Vij, J. Chung, A. Adegunsoye, Chicago, IL, p.A5965 104 Anti-tRNA Synthetase and Anti-Pm/Scl Antibody Status Is Associated with Distinct Immunophenotypes Irrespective of Clinical Classification/ E.M. Wilfong, K.N. Vowell, L.J. Crofford, P.L. Kendall, Nashville, TN, p.A5966 105 Relationship Between Interstitial Pneumonia Related Systemic Sclerosis and Esophageal Motility Abnormalities/ K. Hara, K. Yamaguchi, T. Maeno, T. Hisada, Maebashi, Gunma, Japan, p.A5967 106 A Single Center Experience of Pneumonitis After Immune Checkpoint Inhibitor Therapy/ A.J. Heckman, M. Kwon, V. Arunthari, Y. Lou, R. Manochakian, R. Grage, C. Rojas, N.M. Patel, Jacksonville, FL, p.A5968 107 Incidence of Nivolumab-Induced Pneumonitis and Interstitial Lung Disease (ILD) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Combined Analysis of Four Phase III Randomized Controlled Trials/ P.P. Kyaw, S. Ball, M.H. Zaw, A. Sultan, F. Mogollon-Duffo, P. White, M. Song, K.Z. Thein, Springfield, IL, p.A5969 108 Pulmonary Side Effects of Small Molecule Janus Kinase Inhibitors: Meta-Analysis and Systematic Review/ H. Barnes, J.K. Khoo, S. Key, I. Glaspole, A. Ostor, Melbourne, Australia, p.A5970 109 Lung Allocation Score Should Be Implemented in China/ C.R. Ju, Q. Lian, B. Wei, X. Xu, R. Chen, J. He, Guangzhou, China, p.A5971 110 Bone Marrow Complications in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients/ S. Hannan, I. Popescu, S. Winters, C. Iasella, H. Mannem, E. McNally, V. Hanumanthu, E.A. Lendermon, G. Bullock, J.K. Alder, M. Armanios, J.F. McDyer, Pittsburgh, PA, p.A5972 111 A Study to Evaluate the Effect of Statin Use on Allograft Function and Survival After Lung Transplantation/ N. Bhan, M. Mohanka, S. Bollineni, J. Mullins, V. Kaza, J. Joerns, F. Torres, A. Banga, Dallas, TX, p.A5973 112 Pharmacologic Prevention of Atrial Fibrillation After Lung Transplantation/ J. Ku, S. Codella, M. Bocchese, J. Galli, Philadelphia, PA, p.A5974 113 L-CsA, a Liposomal Formulation of Cyclosporine A, Demonstrates Therapeutic Potential for Bronchiolitis Obliterans Syndrome (BOS)/ N.R. Henig, K. Hoffmann, O. Denk, G. Boerner, Menlo Park, CA, p.A5975 114 Spectrum of Abnormalities on Cardiac Magnetic Resonance Imaging Among Patients with Pulmonary Hypertension and Association with Outcomes After Lung Transplantation/ F. Woll, H. Ali, M. Mohanka, S. Bollineni, J. Mullins, J.O. Joerns, V. Kaza, F. Torres, A. Banga, Dallas, TX, p.A5976 115 Effect of Graft Side Perfusion Mismatch on Outcomes in Single Lung Transplant/ D. Baumgarten, H. Zhao, Y. Toyoda, N. Shigemura, K.V. Shenoy, F.C. Cordova, G.J. Criner, A.J. Mamary, Philadelphia, PA, p.A5977 116 Incidence, Risk Factors and Outcomes of Idiopathic Pneumonia Syndrome After Allogeneic Hematopoietic Cell Transplantation/ D. Wenger, M. Triplette, K.A. Crothers, G.-S. Cheng, J. Hill, F. Milano, S. Shahrir, G. Schoch, L.K. Vande Vusse, Seattle, WA, p.A5978 117 Increased Mortality in Lung Transplant Recipients with Aspiration and Without Gastroesophageal Reflux/ J. Gagermeier, V. Ananthanarayanan, H. Abera, R. Mahmood, R. Nigdelioglu, V. Mukund, Maywood, IL, p.A5979 118 Lung Transplantation for the Treatment of Irreversible Acute Respiratory Distress Syndrome/ T. Harano, J. Ryan, M.R. Morrell, J.D. Luketich, P. Sanchez, Pittsburgh, PA, p.A5980 ATS 2019 • Dallas, TX WEDNESDAY • MAY 22 325 WEDNESDAY MORNING